Association of antiviral use for influenza among non-severe cases with subsequent hospitalization and mortality

BACKGROUND: Evidence regarding a preventive impact of antiviral medication for influenza on hospitalization or mortality among non-severe cases is scarce. The objective of this study was to assess the association between the use of antiviral medications in non-hospitalized patients with influenza and their subsequent hospitalization and mortality. METHODS: This multi-center retrospective cohort study used TriNetX, a global database to assess the clinical impact of antiviral medications (oseltamivir, laninamivir, zanamivir, peramivir, and baloxavir) for influenza among non-hospitalized patients. The outcomes included hospitalization, emergency department visit, intensive care unit (ICU) admission, and mortality between 3 and 30 days following influenza diagnosis with the 2-day window period between diagnosis and antiviral administration. Propensity score matching with a 1:1 ratio was conducted to estimate the risk ratio (RR). RESULTS: A total of 1,016,581 patients with influenza were identified. After matching, 426,275 patients from each cohort were compared. The antiviral-treated group was associated with lower risks of hospitalization (RR 0.91; 95% confidence interval 0.85-0.95; p < 0.001); emergency department visits (RR 0.80; 95% CI 0.79-0.82; p < 0.001), ICU admission (RR 0.84; 95% CI 0.73-0.97; p = 0.016); and mortality (RR 0.60; 95% CI 0.47-0.77; p < 0.001). The sensitivity analysis revealed that the statistical significance in hospitalization was maintained by replacing the 2-day window period with 0 days (RR 0.82; 95% CI 0.79-0.84; p < 0.001). The sensitivity analysis limited to those aged 2 to 64 years without any high-risk comorbidities in the antiviral-treated group compared to the antiviral-untreated group showed fewer outcome events for hospitalization (RR 0.76; 95% CI 0.68-0.85; p < 0.001); ED visit (RR 0.68; 95% CI 0.65-0.71; p < 0.001); and ICU admission (RR 0.48; 95% CI 0.30-0.78; p = 0.002). CONCLUSIONS: Antiviral treatment was negatively associated with hospitalization, ICU admission, and mortality. The results need to be interpreted with caution, given limitations.

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2026-04-06
DOI
https://doi.org/10.1186/s12916-026-04841-9
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of antiviral use for influenza among non-severe cases with subsequent hospitalization and mortality

Taito Kitano, Sayaka Yoshida, Shinya Tsuzuki
BMC Medicine
Influenza Virus Research Studies
article

Association of antiviral use for influenza among non-severe cases with subsequent hospitalization and mortality

Taito Kitano, Sayaka Yoshida, Shinya Tsuzuki
article en

Abstract

BACKGROUND: Evidence regarding a preventive impact of antiviral medication for influenza on hospitalization or mortality among non-severe cases is scarce. The objective of this study was to assess the association between the use of antiviral medications in non-hospitalized patients with influenza and their subsequent hospitalization and mortality. METHODS: This multi-center retrospective cohort study used TriNetX, a global database to assess the clinical impact of antiviral medications (oseltamivir, laninamivir, zanamivir, peramivir, and baloxavir) for influenza among non-hospitalized patients. The outcomes included hospitalization, emergency department visit, intensive care unit (ICU) admission, and mortality between 3 and 30 days following influenza diagnosis with the 2-day window period between diagnosis and antiviral administration. Propensity score matching with a 1:1 ratio was conducted to estimate the risk ratio (RR). RESULTS: A total of 1,016,581 patients with influenza were identified. After matching, 426,275 patients from each cohort were compared. The antiviral-treated group was associated with lower risks of hospitalization (RR 0.91; 95% confidence interval 0.85-0.95; p < 0.001); emergency department visits (RR 0.80; 95% CI 0.79-0.82; p < 0.001), ICU admission (RR 0.84; 95% CI 0.73-0.97; p = 0.016); and mortality (RR 0.60; 95% CI 0.47-0.77; p < 0.001). The sensitivity analysis revealed that the statistical significance in hospitalization was maintained by replacing the 2-day window period with 0 days (RR 0.82; 95% CI 0.79-0.84; p < 0.001). The sensitivity analysis limited to those aged 2 to 64 years without any high-risk comorbidities in the antiviral-treated group compared to the antiviral-untreated group showed fewer outcome events for hospitalization (RR 0.76; 95% CI 0.68-0.85; p < 0.001); ED visit (RR 0.68; 95% CI 0.65-0.71; p < 0.001); and ICU admission (RR 0.48; 95% CI 0.30-0.78; p = 0.002). CONCLUSIONS: Antiviral treatment was negatively associated with hospitalization, ICU admission, and mortality. The results need to be interpreted with caution, given limitations.

BMC Medicine
National Archives and Records Administration (US), University of Antwerp (BE), Institute for Security Studies (KE), Taiwan Centers for Disease Control (TW), Nara Medical University (JP)
Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 23%
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.